LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Accueil・Liste d'Actions・Sana Biotechnology Inc

Sana Biotechnology Inc

Fermé

SecteurSoins de santé

2.67 -10.1

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.67

Max

2.74

Chiffres clés
By Trading Economics
Revenu	12M -47M
BPA	-0.171
Employés	142
EBITDA	23M -35M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+265.67% upside

Dividendes
By Dow Jones
Prochains Résultats	7 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-68M 893M
Ouverture précédente	12.77
Clôture précédente	2.67

Sentiment de l'Actualité

By Acuity

25%

75%

64 / 344 Classement par Healthcare

Sana Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juin 2026, 19:20 UTC

Principaux Mouvements du Marché

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 juin 2026, 21:27 UTC

Résultats

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 juin 2026, 20:19 UTC

Acquisitions, Fusions, Rachats

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 juin 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 juin 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 juin 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 juin 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 juin 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 juin 2026, 18:33 UTC

Acquisitions, Fusions, Rachats

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 juin 2026, 17:50 UTC

Résultats

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 juin 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 juin 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 juin 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 juin 2026, 15:44 UTC

Acquisitions, Fusions, Rachats

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 juin 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 juin 2026, 15:25 UTC

Résultats

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 juin 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 juin 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 juin 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 juin 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 juin 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparaison

Variation de prix

Sana Biotechnology Inc prévision

Objectif de Prix

By TipRanks

265.67% hausse

Prévisions sur 12 Mois

Moyen 9.8 USD 265.67%

Haut 16 USD

Bas 7 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

64 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.